<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/EFC615CC-2FF3-4CBF-9D5C-5989DC6465E9" ns1:id="EFC615CC-2FF3-4CBF-9D5C-5989DC6465E9"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/2AAED3E5-009C-4FF9-A47D-AED4812AF3D8" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/16825DC3-D7E5-4726-B60E-2FDB985F2911" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/16825DC3-D7E5-4726-B60E-2FDB985F2911" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/B0D7E9B8-D50A-4D3A-9569-C0F65624E298" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/30F84862-BC6D-48AB-A4A8-D26EFF5E68F8" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2021-04-29T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/9C485261-4886-44C3-8E3E-0E360F55BFA6" ns1:rel="FUND" ns1:start="2018-11-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">104517</ns2:identifier></ns2:identifiers><ns2:title>Purification of Adeno-Associated Virus (AAV) by continuous Chromatography</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>ISCF</ns2:leadFunder><ns2:abstractText>The project aims to increase yields of Adeno-Associated Viral (AAV) vectors for human gene therapy studies through the improved purification processes and through the adoption of continuous chromatography approaches. The project aims to develop purification processes with improved yields and robustness that can be readily scaled to those required for in-market requirements at a reduced cost of goods than is currently being achieved for these vectors, addressing the critical needs to increase the supply and costs of these medicines.</ns2:abstractText></ns2:project>